AstraZeneca Pharma India Ltd. — Major Shareholding Notification 2019

Apr 11, 2019

AstraZeneca Pharmaceuticals Aktiebolag SE-151 85 Södertälje, Sweden T: +46 8 553 260 00 F: +46 8 553 290 00 astrazeneca.com

The Manager – Listing BSE Limited Corporate Relationship Department P J Towers, Dalal Street Fort, Mumbai 400 001

The Manager - Listing National Stock Exchange of India Ltd. Exchange Plaza, 5th Floor Plot No. C/1, G Block Bandra - Kurla Complex Mumbai - 400 051

Date: 20190402

Dear Sirs.

Sub: Disclosure under Regulation 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Please find enclosed the relevant disclosure required to be made by the Promoter (AstraZeneca Pharmaceuticals AB, Sweden) in terms of the requirements of Regulation 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011, with regard to equity shares of AstraZeneca Pharma India Limited, held by the promoter, as on March 31, 2019.

Please take note of the above and acknowledge receipt.

Thanking you,

Yours faithfully, for AstraZeneca Pharmaceuticals AB

Come Berk

Yvonne Bertlin Director

CC: The Company Secretary & Legal Counsel, AstraZeneca Pharma India Limited. Block N1, 12th Floor Manyata Embassy Business Park Rachenahalli, Outer Ring Road Bangalore - 560045 India

Reg Office AstraZeneca Pharmaceuticals Aktiebolag SE-151 85 Södertälje, Sweden Reg No 556023-0657

Format for Disclosures under Regulation 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Part-A

1.	Name of the Target Company (TC)	AstraZeneca Pharma India Limited
2.	Name(s) of the stock exchange(s) where the sharesof the TC are listed	a) BSE Limitedb) National Stock Exchange of India Limited
3.	Particulars of the shareholder(s):a. Name of person(s) together with PersonsActing in Concert (PAC) whose totalholding (including that in the form of shares,warrants, convertible securities and anyother instrument that would entitle theholder to receive shares in the TC) is morethan 25% of the voting rights of the TC.$\alpha$ rb. Names of promoter(s), member of thepromoter group and PAC with him.	NoneAstraZeneca Pharmaceuticals AB, Sweden
4.	Particulars of the shareholding of person(s)mentioned at (3) above	Number ofshares	% w.r.t. totalshare / votingcapital whereapplicable	% of totaldilutedshare/votingcapital of TC (*)
	As of March 31st of the year, holding of:Sharesa)Voting Rights (otherwise than byb)shares)c) Warrantsd) Convertible SecuritiesAny other instrument that would entitlee)the holder to receive shares in the TC	18,750,000	75.00%	Not applicablesince there areno outstandingconvertiblesecurities /warrants
	Total	18,750,000	75.00 %

(*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

For AstraZeneca Pharmaceuticals AB

Would Bark

Authorized Signatory

Place: Sweden Date: 20190402